A cannabinoid drug developer has filed a patent for its colon cancer treatment.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) filed a U.S. provisional patent for its “Composition and Method for Treating Colon Cancer with Cannabinoids,” on Wednesday, the company said in a statement.
The formula uses a potent cocktail of non-psychoactive cannabinoids, which allow people to go through the treatment without ever feeling high. The cannabinoids have anti-tumour properties, Cannabics said, which could be used as a possible adjunct or stand-alone therapy to fight colon cancer.
The novel formulation was discovered while the company tested how cannabis could be used to fight gastrointestinal cancers.
In April, the company said it completed a preclinical trial that used a high dose of the the cannabinoid cannabidivarin (CBDV) and cannabigerolic acid (CBGA) to fight colon cancer.
The two cannabinoids have anti-tumour properties, the company said — but only when used against certain cancers.
So, no silver bullet for the world’s deadliest disease has been discovered yet. But cannabis legalization in countries like Canada has helped reduce stigma around the drug, and helped attract research money to test how weed can be used in novel ways.
The company is American, but does most of its work at its research facility in Tel Aviv, Israel. Cannabics is licensed by the Israeli Ministry of Health to do scientific and clinical research on how cannabinoids can be used to fight cancer.
According to the company website, it hopes to one day use cannabinoids to personalize cancer treatments and therapies.
“By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy,” it says.
Top image: press photo